Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Pyridam Farma Tbk's revenue for the
three
months ended in Jun. 2026 was Rp850,990 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was Rp2,992,542 Mil.
PT Pyridam Farma Tbk's Revenue per Share for the
three
months ended in Jun. 2026 was Rp75.73.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was Rp257.32.
Warning Sign:
PT Pyridam Farma Tbk revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of PT Pyridam Farma Tbk was 0.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -5.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 10.90% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 15.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, PT Pyridam Farma Tbk's highest 3-Year average Revenue per Share Growth Rate was 44.50% per year. The lowest was -5.10% per year. And the median was 9.15% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, PT Pyridam Farma Tbk's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Pyridam Farma Tbk Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Pyridam Farma Tbk's Revenue distribution charts can be found below:
* The bar in red indicates where PT Pyridam Farma Tbk's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp2,992,542 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Pyridam Farma Tbk (ISX:PYFA) has a Revenue of Rp2,992,542 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on PT Pyridam Farma Tbk and its competitors.
Is PT Pyridam Farma Tbk's Revenue too high?
PT Pyridam Farma Tbk's current Revenue is Rp2,992,542 Mil. Overall, PT Pyridam Farma Tbk has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PT Pyridam Farma Tbk's Revenue compare to ZTS and UTHR?
PT Pyridam Farma Tbk's Revenue of Rp2,992,542 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on PT Pyridam Farma Tbk and its competitors. PT Pyridam Farma Tbk's current Revenue is Rp2,992,542 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Pyridam Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Pyridam Farma Tbk (ISX:PYFA) is currently considered Fairly Valued. The stock's GF Value™ is Rp230.31, compared to a current price of Rp232.00 — trading 0.7% above its estimated fair value. The current Revenue is Rp2,992,542 Mil. PT Pyridam Farma Tbk's overall GF Score™ is 65/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For PT Pyridam Farma Tbk (ISX:PYFA), the current Revenue is Rp2,992,542 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Pyridam Farma Tbk (ISX:PYFA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Pyridam Farma Tbk stock appears to be overvalued.
The current stock price of Rp232.00 is trading 0.7% above its estimated GF Value™ of Rp230.31.
GuruFocus considers PT Pyridam Farma Tbk to be Fairly Valued.
Key valuation signals for ISX:PYFA:
Revenue: Rp2,992,542 Mil
GF Value™: Rp230.31 vs. price of Rp232.00 (0.7% above fair value)
No single metric tells the full story. See the ISX:PYFA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Pyridam Farma Tbk is engaged in the production and development of pharmaceutical medicines and the trading of medical equipment. It manufactures products namely Antibiotics, Vitamins, Supplements, and Traditional herbal care. It operates through two segments namely Pharmaceutical products, Esthetics, and Toll manufacturing services; and Medical equipment Products segment. The company derives maximum revenue from Pharmaceutical products, Esthetics, and Toll manufacturing services. The company's products include consumer health, Derma, prescription, and biomedilab.
65GF Score
Get the complete analysis for ISX:PYFA
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:PYFA has been successfully added to your 
